GSK-3 protein and the heart: friend or foe?

Metabolic syndrome manifesting as obesity, insulin resistance and type 2 diabetes mellitus is currently pandemic. Each of these, in its own right, is strongly related to the development of cardiovascular disease. The cardiomyopathy associated with these disorders is characterised by curtailed glucos...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	B. Huisamen, A. Lochner
Formato:	article
Lenguaje:	EN
Publicado:	South African Heart Association 2017
Materias:	glycogen synthase kinase-3 (gsk-3) heart health Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/a80b9bebb8ff412ab3e03c2e2ac3c918
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a80b9bebb8ff412ab3e03c2e2ac3c918
record_format	dspace
spelling	oai:doaj.org-article:a80b9bebb8ff412ab3e03c2e2ac3c9182021-11-22T10:30:34ZGSK-3 protein and the heart: friend or foe?10.24170/7-1-19671996-67412071-4602https://doaj.org/article/a80b9bebb8ff412ab3e03c2e2ac3c9182017-04-01T00:00:00Zhttps://www.journals.ac.za/index.php/SAHJ/article/view/1967https://doaj.org/toc/1996-6741https://doaj.org/toc/2071-4602Metabolic syndrome manifesting as obesity, insulin resistance and type 2 diabetes mellitus is currently pandemic. Each of these, in its own right, is strongly related to the development of cardiovascular disease. The cardiomyopathy associated with these disorders is characterised by curtailed glucose uptake and utilisation, elevated risk of damage after ischaemia and contractile dysfunction. Current research have indicated that the serine/threonine kinase, glycogen synthase kinase 3 (GSK-3), may play a central role in the development of all these dysfunctions. The development of new generations of inhibitors of this kinase, has renewed interest in its utilisation as therapeutic target. This review has therefore focused on the role of GSK-3 in the development of the obesity-related cardiomyopathy and has highlighted and discussed the detrimental as well as beneficial effects of the GSK-3 inhibitors that are currently available. We have discussed the different roleplayers such as the insulin signalling pathway, modulation of apoptosis and mitochondrial function, SERCA2 expression and regulation of the development of hypertrophy in the context of GSK-3 activity.B. HuisamenA. LochnerSouth African Heart Associationarticleglycogen synthase kinase-3 (gsk-3)heart healthDiseases of the circulatory (Cardiovascular) systemRC666-701ENSA Heart Journal, Vol 7, Iss 1 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	glycogen synthase kinase-3 (gsk-3) heart health Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	glycogen synthase kinase-3 (gsk-3) heart health Diseases of the circulatory (Cardiovascular) system RC666-701 B. Huisamen A. Lochner GSK-3 protein and the heart: friend or foe?
description	Metabolic syndrome manifesting as obesity, insulin resistance and type 2 diabetes mellitus is currently pandemic. Each of these, in its own right, is strongly related to the development of cardiovascular disease. The cardiomyopathy associated with these disorders is characterised by curtailed glucose uptake and utilisation, elevated risk of damage after ischaemia and contractile dysfunction. Current research have indicated that the serine/threonine kinase, glycogen synthase kinase 3 (GSK-3), may play a central role in the development of all these dysfunctions. The development of new generations of inhibitors of this kinase, has renewed interest in its utilisation as therapeutic target. This review has therefore focused on the role of GSK-3 in the development of the obesity-related cardiomyopathy and has highlighted and discussed the detrimental as well as beneficial effects of the GSK-3 inhibitors that are currently available. We have discussed the different roleplayers such as the insulin signalling pathway, modulation of apoptosis and mitochondrial function, SERCA2 expression and regulation of the development of hypertrophy in the context of GSK-3 activity.
format	article
author	B. Huisamen A. Lochner
author_facet	B. Huisamen A. Lochner
author_sort	B. Huisamen
title	GSK-3 protein and the heart: friend or foe?
title_short	GSK-3 protein and the heart: friend or foe?
title_full	GSK-3 protein and the heart: friend or foe?
title_fullStr	GSK-3 protein and the heart: friend or foe?
title_full_unstemmed	GSK-3 protein and the heart: friend or foe?
title_sort	gsk-3 protein and the heart: friend or foe?
publisher	South African Heart Association
publishDate	2017
url	https://doaj.org/article/a80b9bebb8ff412ab3e03c2e2ac3c918
work_keys_str_mv	AT bhuisamen gsk3proteinandtheheartfriendorfoe AT alochner gsk3proteinandtheheartfriendorfoe
_version_	1718417752910200832

GSK-3 protein and the heart: friend or foe?

Ejemplares similares